8-K: Edwards Lifesciences Reports Strong Third Quarter Growth Driven by TAVR and TMTT

Edwards Lifesciences announced a robust third quarter with sales growth driven by its TAVR and TMTT segments, alongside the completion of the Critical Care divestiture.

Summary

• Edwards Lifesciences reported a 9% increase in third-quarter sales from continuing operations, or 10% on a constant currency basis.
• Transcatheter Aortic Valve Replacement (TAVR) sales grew by 6%, or 7% on a constant currency basis, reaching $1.0 billion.
• Transcatheter Mitral and Tricuspid Therapies (TMTT) sales saw a significant 73% increase, reaching $91 million.
• The company completed the sale of its Critical Care business in the third quarter, resulting in a one-time gain.
• Adjusted earnings per share (EPS) were $0.67, slightly above the company's guidance.
• The company repurchased $1.0 billion of stock during the quarter and has $1.4 billion remaining under its current authorization.
• Full-year sales growth guidance remains unchanged at 8% to 10%.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong sales growth, particularly in the TMTT segment, and the company's ability to exceed its own guidance. The divestiture of the Critical Care business and the share repurchase program also contribute to the positive outlook.

Positives

• Strong sales growth in both TAVR and TMTT segments indicates market demand for Edwards' products.
• The successful commercial launches of PASCAL and EVOQUE systems are contributing to TMTT growth.
• The divestiture of the Critical Care business allows Edwards to focus on its core structural heart business.
• The company's adjusted EPS exceeded its own guidance, demonstrating strong financial performance.
• The share repurchase program indicates confidence in the company's future prospects.
• The company's gross profit margin was 80.7%, compared to 79.9% in the same period last year.

Negatives

• Selling, general, and administrative expenses increased to $421 million, or 31.1% of sales, compared to $382 million in the prior year.
• Research and development expenses increased 4% to $253 million, or 18.7% of sales.

Risks

• Hospitals and physicians are experiencing capacity constraints, which could impact TAVR procedure volumes.
• The company faces risks and uncertainties associated with clinical trial outcomes and regulatory approvals.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Edwards expects fourth quarter sales of $1.33 to $1.39 billion and Q4 EPS of $0.53 to $0.57. The company's full-year sales growth guidance of 8% to 10% remains unchanged.

Management Comments

• Bernard Zovighian, CEO, stated that the company took important actions to sharpen its focus on structural heart by divesting Critical Care and investing in platforms to impact more patients.
• Mr. Zovighian also noted that third quarter total company sales growth from continuing operations of 10% reflected strong contributions from both TAVR and the rapidly growing TMTT product group.
• Management sees expanded opportunities to meet the needs of a highly diverse group of patients suffering from aortic stenosis, aortic regurgitation, mitral and tricuspid disease, and structural heart failure.

Industry Context

The results reflect a continued trend of growth in the structural heart market, particularly in transcatheter therapies. The company's focus on innovation and clinical evidence positions it well within the competitive landscape.

Comparison to Industry Standards

• Edwards' TAVR growth of 6% is in line with the overall market growth, but the 73% growth in TMTT is significantly higher than the average growth rate of other companies in the space, such as Abbott and Medtronic, indicating a strong market position for their PASCAL and EVOQUE systems.
• The company's gross profit margin of 80.7% is also higher than the industry average, which is typically in the range of 70-75%, suggesting strong pricing power and efficient operations.
• The company's investment in R&D at 18.7% of sales is also higher than the industry average, which is typically in the range of 10-15%, indicating a strong commitment to innovation and future growth.

Stakeholder Impact

• Shareholders will benefit from the strong financial performance and share repurchase program.
• Employees may experience changes due to the workforce realignment.
• Patients will benefit from the company's continued innovation in structural heart therapies.
• Customers will have access to new and improved treatment options.

Next Steps

• The company will present pivotal TAVR and TMTT clinical evidence at the TCT conference next week.
• The company will continue the commercial launches of the PASCAL and EVOQUE systems.
• The company will continue to invest in its transcatheter valve innovations.

Key Dates

Keywords

TAVR, TMTT, Edwards Lifesciences, Structural Heart, PASCAL, EVOQUE, Surgical Structural Heart, Transcatheter, Medical Devices, Financial Results